Results 231 to 240 of about 15,220 (247)

Plasma concentration of ?-methyldopa and sulphate conjugate after oral administration of methyldopa and intravenous administration of methyldopa and methyldopa hydrochloride ethyl ester

European Journal of Clinical Pharmacology, 1975
The plasma concentrations of free alpha-methyldopa and methyldopa sulphate conjugate were measured in 7 hypertensive patients with normal renal function following alpha-methyldopa (1 g) orally. Five of these patients subsequently received alpha-methyldopa ethyl ester (250 mg) (methyldopate) intravenously and two further patients received 250 mg of ...
J A Saavedra, J L Reid, C T Dollery, W Jordan, M D Rawlins   +4 more
openaire   +3 more sources

Methyldopa kinetics before and after ingestion of methyldopa for eight weeks

European Journal of Clinical Pharmacology, 1995
Methyldopa urine and plasma levels and urine metabolite levels were assessed following intravenous (IV) and oral (PO) methyldopa before, and after ingestion of methyldopa (500 mg) daily for eight weeks. There was no increase in (estimated) methyldopa absorption (8.4%) or renal clearance (PO 13.9%, IV 2.33%) after the eight weeks of methyldopa ingestion.
Yun K. Tam, E. Burgess, Norman R.C. Campbell, Andrej Skerjanec, Susan Robertson   +4 more
openaire   +3 more sources

Clinical Pharmacokinetics of Methyldopa

Clinical Pharmacokinetics, 1982
Absorption of methyldopa from the gastrointestinal tract is incomplete and variable; bioavailability after oral administration is about 25% (range 8 to 62%). The average time to reach maximum plasma concentration (tmax) [chemically determined] is 2 hours, when the maximum plasma concentration of active drug accounts for 50% of the radioactivity, the ...
Hans Erik Rugstad, Erik Myhre, Tage Hansen   +2 more
openaire   +2 more sources

Effects of Methyldopa in Hypertension

JAMA, 1964
Methyldopa demonstrated antihypertensive activity when prescribed in initial amounts of 1 gm daily in four divided doses to 51 patients with mild to moderate hypertension. The mean arterial pressure was reduced by an average of 34/18 mm Hg in the supine position and 34/24 mm Hg in the standing position.
openaire   +3 more sources

AUTOANTIBODIES AND METHYLDOPA

The Lancet, 1968
T. E. W. Feltkamp, J. J. van Loghem, C. P. Engelfriet   +2 more
openaire   +3 more sources

MARROW APLASIA AND METHYLDOPA

The Lancet, 1968
R.L. Ward, H.D. Vyas, N.G. Durgé
openaire   +3 more sources

Methyldopa in Hypertension [PDF]

BMJ, 1966
openaire   +1 more source

HEMATOLOGICAL EFFECTS OF METHYLDOPA

The Lancet, 1967
A.J. Barnett, S. Cantor
openaire   +3 more sources

METHYLDOPA AND AMITRIPTYLINE

The Lancet, 1965
openaire   +3 more sources

THE COOMBS TEST AND METHYLDOPA

The Lancet, 1968
B.I. Joffe, I. Spector
openaire   +3 more sources